Volume 3.05 | Feb 10

Cord Blood News 3.05, February 10, 2011
     In this issue: Science News | Current Publications | Industry News | Policy News | Events  
Dendritic Cells with Lymphocyte Stimulating Activity Differentiate from Human CD133 Positive Precursors
Researchers have addressed whether human cord blood cells selected for CD133 can generate dendritic cells, and Langerhans cells in particular, in conditions which promote that generation from CD34+ progenitors. [Blood]


social_default_facebook_icon.jpg Cell Therapy News is now on Facebook. Join us!

social_default_twitter_icon.jpg Follow us on Twitter!  @Cord_Blood_News

Interested in recruiting talented individuals? Post your career opportunities in Cord Blood News at no cost. Contact us at [email protected]


Girl with Cerebral Palsy Treated with Own Cord Blood Stem Cells
Medical doctors are treating cerebral palsy patients who have their own cord blood stored, in a clinical trial. [Cryo-Save AG Press Release]


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

Efficient Generation of Transgene-Free Induced Pluripotent Stem Cells from Normal and Neoplastic Bone Marrow and Cord Blood Mononuclear Cells
Scientists demonstrated that induced pluripotent stem cells free of transgene and vector sequences could be efficiently generated from human bone marrow and cord blood mononuclear cells using non-integrating episomal vectors. [Blood]

Tregs Prevent GvHD and Promote Immune Reconstitution in HLA-Haploidentical Transplantation
The present study evaluated the impact of early infusion of T regulatory cells, followed by conventional T cells, on GvHD prevention and immunological reconstitution, in 28 patients with high risk hematological malignancies who underwent HLA-haploidentical hematopoietic stem cell transplantation. [Blood]

CD34+ Hematopoietic Precursors Are Present in Human Decidua and Differentiate into Natural Killer Cells Upon Interaction with Stromal Cells
Researchers discovered CD34+ hematopoietic precursors in human decidua (dCD34+). They show that dCD34+ cells differ from cord blood- or peripheral blood-derived CD34+ precursors. [Proc Natl Acad Sci U S A]

Clinical-Scale Cultures of Cord Blood CD34+ Cells to Amplify Committed Progenitors and Maintain Stem Cell Activity
Researchers developed a clinical-scale cord blood cell ex vivo procedure to enable an extensive expansion of committed progenitors, colony forming cells, without impairing very primitive hematopoietic stem cells. [Cell Transplant]

Serious Infection Risk and Immune Recovery After Double Unit Cord Blood Transplantation Without Anti-Thymocyte Globulin
Results suggest that double unit cord blood transplantation (CBT) without anti-thymocyte globulin (ATG) is associated with prompt T-cell recovery, and unlike CBT incorporating ATG, infection is rarely a primary cause of death. [Biol Blood Marrow Transplant]

Long-Term Outcome of Human Herpesvirus-6 Encephalitis After Allogeneic Stem Cell Transplantation
Researchers surveyed 197 patients who underwent allogeneic hematopoietic stem cell transplantation between January 2004 and March 2008 at our institution, and 8 (4.0%) were diagnosed as having human herpesvirus-6 encephalitis. [Biol Blood Marrow Transplant]

A Human Thymic Epithelial Cell Culture System for the Promotion of Lymphopoiesis from Hematopoietic Stem Cells
Researchers report for the first time a human thymic epithelial cell line that supports lymphopoiesis from cord blood and bone marrow hematopoietic progenitor cell. [Exp Hematol]

Treosulfan-Based Preparative Regimens for Allo-HSCT in Childhood Hematological Malignancies: A Retrospective Study on Behalf of the EBMT Pediatric Diseases Working Party
Children with high-risk and advanced hematological malignancies and high-risk of life-threatening regimen-related toxicity can be transplanted effectively and safely using treosulfan-based regimens. Particularly favorable results were achieved in myeloid malignancies and in children undergoing second hematopoietic stem cell transplantation (HSCT). [Bone Marrow Transplant]


Manufacturing License for Separation of Stem Cells from Cord Blood
Following a successful inspection by the Landesdirektion Leipzig, InnovaStem GmbH has gained the manufacturing license for separation of stem cells from cord blood, according to German Drug Law. [Fraunhofer Institute for Cell Therapy and Immunology IZI Press Release]

Americord Becomes Only Family Cord Blood Bank Headquartered in New York City to Hold State Cord Blood License
Americord Registry  announced that it has obtained a provisional human tissue cord blood banking license from the New York State Department of Health, becoming the first private umbilical cord blood bank headquartered in New York City with the authority to collect umbilical cord blood in the state of New York. [PR Newswire]

Cord Blood America Announces Second Major Placenta, Umbilical Cord Collection Service
Cord Blood America, Inc. announced that it has signed a Supply Agreement with a premier national and international cell and tissue bank to provide placenta, umbilical cord blood and whole umbilical cord collection services for research purposes. [Cord Blood America, Inc. Press Release]

Cellerant Therapeutics Announces Key Additions to Senoir Management Team
Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced that it has strengthened its senior management team with the appointments of Margaret Dillon, Ph.D., as Vice President of Regulatory Affairs and Robert Tressler, Ph.D., as Vice President of Research & Development. [Cellerant Therapeutics Inc. Press Release]

Enabling the Next Biomedical Revolution
In his State of the Union address President Obama singled out biomedical innovation as a key driver of America’s future prosperity. This sector has indeed generated tens of thousands of jobs, attracted billions in investment and created advanced medical treatments for Americans. [Forbes]

Senator Wants to Get the Word Out on Umbilical Cord Blood
Senator Margaret Sitte, R-Bismarck, is pushing a bill that would require the state to distribute information on the use of umbilical cord blood. [North Dakota Senate Appropriations Committee, United States]

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


Visit our events page to see a complete list of events in the cord blood community.


Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Cell Therapy Manufacturing Manager (Opexa Therapeutics)

Field Applications Specialist – Cell Therapy (Medical) (Pall Corporation)

Postdoctoral Positions – Stem Cell Biology (Joslin Diabetes Center/Harvard Stem Cell Institute)

Postdoctoral Position – Germline Stem Cells (R. L. Brinster, School of Veterinary Medicine, University of Pennsylvania)

Assistant Professor (University of Pittsburgh School of Medicine, Center for Cellular and Molecular Engineering)

Associate Scientist – Oncology (St. Jude Children’s Research Hospital)

Postdoctoral Scholar (University of Iowa Carver College of Medicine)

Postdoctoral Fellow (The Henry M. Jackson Foundation)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with the Connexon Creative Job Board at no cost.

Visit here to post your career opportunities.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Cord Blood News: Archives | Events | Contact Us